CJC-1295 Without DAC | Research Use Only

What it is

CJC-1295 without DAC is a synthetic growth hormone-releasing hormone analog commonly discussed in the research space as Modified GRF (1-29). Unlike the DAC-conjugated version, it does not include the Drug Affinity Complex used for albumin binding and extended circulation time, which is why it is generally studied as a shorter-acting GHRH analog in GH-axis and endocrine signaling research. Sources: PubChem CJC1295 Without DAC, FDA PCAC briefing document 2024.

Origins and scientific context

CJC-1295 without DAC emerged from efforts to improve the stability of native GHRH(1-29) while avoiding the prolonged exposure profile produced by DAC-mediated albumin binding. FDA’s 2024 briefing materials specifically note that there have been many modifications to GHRH over time, including a version synthesized without DAC, which FDA identifies as “CJC-1295 (free base)” in that document. In research and product literature, this non-DAC version is frequently equated with Modified GRF (1-29), although precise naming can vary across sources, so researchers usually distinguish carefully between the DAC and non-DAC forms. Sources: FDA PCAC briefing document 2024, FDA points to consider 2024, PubChem CJC1295 Without DAC.

Molecular profile

PubChem lists CJC1295 Without DAC with molecular formula C152H252N44O42. Public chemical references distinguish it from DAC-conjugated CJC-1295, which has a different composition because of the added albumin-binding modification. Sources: PubChem CJC1295 Without DAC, PubChem CJC-1295 with DAC.

Scientific overview

CJC-1295 without DAC is studied because GHRH analogs can stimulate the GH/IGF-1 axis, but the non-DAC version is generally discussed as having a shorter activity window than DAC-conjugated CJC-1295. That distinction matters in research models focused on pulsatile GH signaling, endocrine timing, and comparisons between shorter- and longer-acting secretagogue approaches. FDA briefing materials also emphasize that multiple similarly named CJC-1295-related substances exist, which is one reason the DAC versus non-DAC distinction is important in both laboratory and regulatory contexts. Sources: FDA PCAC briefing document 2024, FDA points to consider 2024.

What researchers study with CJC-1295 Without DAC

Common research focus areas include
• Growth hormone and IGF-1 axis modulation
• GHRH receptor signaling and endocrine pharmacology
• Pulsatile growth hormone release models
• Comparative research versus DAC-conjugated GHRH analogs
• Stability-enhanced short-acting GHRH analog design

Sources: PubChem CJC1295 Without DAC, FDA PCAC briefing document 2024.

Regulatory and compliance notice

Research Use Only. Not for human or veterinary use. CJC-1295 without DAC is not FDA-approved. FDA’s 2024 Pharmacy Compounding Advisory Committee materials state that FDA proposed that CJC-1295 (free base) and CJC-1295 acetate not be included on the 503A Bulks List, alongside the DAC forms. FDA’s published meeting materials also show that CJC-1295-related substances were considered as part of that December 4, 2024 advisory process, which is important regulatory context but does not indicate approval. Sources: FDA points to consider 2024, FDA draft questions / vote materials 2024, Federal Register notice.

Citations and references

PubChem. CJC1295 Without DAC compound record, including molecular formula and identifiers.
https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC

PubChem. CJC-1295 compound record for the DAC-conjugated form, useful for comparison with the non-DAC version.
https://pubchem.ncbi.nlm.nih.gov/compound/Cjc-1295

FDA. Pharmacy Compounding Advisory Committee Briefing Document: CJC-1295-related bulk drug substances.Explains that CJC-1295 synthesized without DAC is identified as CJC-1295 (free base) and distinguishes it from DAC forms.
https://www.fda.gov/media/183819/download

FDA. Points to Consider Regarding Whether FDA Should Include Certain Bulk Drug Substances on the 503A Bulks List. States FDA proposed that CJC-1295 (free base) and CJC-1295 acetate not be included on the 503A Bulks List.
https://www.fda.gov/media/183583/download

FDA. Pharmacy Compounding Advisory Committee Meeting Materials / Draft Questions, Dec. 4, 2024. Records the CJC-1295-related substances discussed during the advisory process.
https://www.fda.gov/media/183945/download

Federal Register. Notice of Pharmacy Compounding Advisory Committee Meeting. Lists CJC-1295-related bulk substances discussed for possible inclusion on the 503A Bulks List.
https://public-inspection.federalregister.gov/2024-24828.pdf

One thing to note here: “CJC-1295 without DAC” and “Modified GRF (1-29)” are often treated as the same thing in the research market, but source naming is not always perfectly consistent, so this version keeps the wording careful.